Capacity, Expertise Drive Korea's Emergence As COVID-19-Related Manufacturing Base
You may also be interested in...
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Heads of vaccines development at partners GSK and Sanofi:“This is not a sprint, it’s a marathon.”